or Try an Advanced Search...

    Technical Analysis for OCS - Oculis Holding AG

    Grade Last Price % Change Price Change
    C 11.98 0.04% 0.01
    OCS closed up 0.04 percent on Friday, May 17, 2024, on 9 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Up Down
    Historical OCS trend table...
    Date Alert Name Type % Chg
    Narrow Range Bar Range Contraction 0.00%
    Oversold Stochastic Weakness 0.00%
    Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.04%
    Outside Day Range Expansion 0.04%
    Oversold Stochastic Weakness 0.04%
    NR7 Range Contraction -0.29%
    Narrow Range Bar Range Contraction -0.29%
    Gapped Down Weakness -0.29%
    Oversold Stochastic Weakness -0.29%
    Narrow Range Bar Range Contraction -1.52%
    Older End-of-Day Signals for OCS ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakout 3 days ago
    60 Minute Opening Range Breakdown 4 days ago
    Outside Day 4 days ago
    Fell Below Previous Day's Low 4 days ago
    Rose Above Previous Day's High 4 days ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    OCS Chart by TradingView
    Basic chart:

    Profile

    • Earnings date: Unknown
    Oculis Holding AG, a biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. Its product candidates in development includes OCS-01, a topical retinal candidate for diabetic macular edema; OCS-02, a topical biologic candidate for dry eye disease; and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Lausanne, Switzerland.
    Classification
    Sector: Financial Services
    Industry: Shell Companies
    Keywords: Medicine Biopharmaceutical Disease Organ Systems Diabetes Ophthalmology Glaucoma Diabetic Retinopathy Macular Edema Diabetic Macular Edema Blindness Retinopathy Dry Eye Disease Ophthalmic Diseases

    Is OCS a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 9 Oculis Holding reports Q1 results
    May 8 Oculis Reports Q1 2024 Financial Results and Provides Company Updates
    May 8 Oculis Announces Completion of Enrollment in Phase 2 Randomized Controlled ACUITY Trial with OCS-05 for Acute Optic Neuritis
    Apr 29 Oculis Publishes Invitation to the Annual General Meeting
    Apr 22 Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market
    Apr 11 Oculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Market
    Apr 10 Oculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as President of Research & Development
    Apr 8 Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
    Apr 4 Oculis to Participate at Upcoming April Investor Conferences
    Apr 1 Oculis files $300M mixed securities shelf
    See more OCS news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 14.495
    52 Week Low 9.05
    Average Volume 45,473
    200-Day Moving Average 11.61
    50-Day Moving Average 11.89
    20-Day Moving Average 12.31
    10-Day Moving Average 12.19
    Average True Range 0.33
    RSI (14) 45.65
    ADX 15.68
    +DI 24.80
    -DI 25.46
    Chandelier Exit (Long, 3 ATRs) 12.32
    Chandelier Exit (Short, 3 ATRs) 12.70
    Upper Bollinger Bands 13.09
    Lower Bollinger Band 11.53
    Percent B (%b) 0.29
    BandWidth 12.74
    MACD Line 0.02
    MACD Signal Line 0.11
    MACD Histogram -0.0867
    Fundamentals Value
    Market Cap 436.31 Million
    Num Shares 36.4 Million
    EPS -2.69
    Price-to-Earnings (P/E) Ratio -4.45
    Price-to-Sales 510.76
    Price-to-Book 3.79
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 12.19
    Resistance 3 (R3) 12.18 12.11 12.15
    Resistance 2 (R2) 12.11 12.06 12.11 12.14
    Resistance 1 (R1) 12.04 12.03 12.08 12.05 12.13
    Pivot Point 11.97 11.97 11.99 11.97 11.97
    Support 1 (S1) 11.90 11.92 11.94 11.91 11.82
    Support 2 (S2) 11.83 11.89 11.83 11.81
    Support 3 (S3) 11.76 11.83 11.80
    Support 4 (S4) 11.77